Response to the letter to the editor on 'an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy'

Lin Hollis; Agarwal Sonalee; Betts Marissa; Fahrbach Kyle; Chitnis Madhura; Polydefkis Michael

首页> 外文期刊>Expert opinion on pharmacotherapy >Response to the letter to the editor on 'an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy'

【24h】

Response to the letter to the editor on 'an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy'

机译：回应编辑的信函“一个间接治疗比较Patisiran和Tafamidis治疗遗传性Transthyretin介导的淀粉样蛋白病变淀粉样蛋白病变的间接治疗比较”

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Expert opinion on pharmacotherapy》 |2019年第12期|共2页
作者
Lin Hollis; Agarwal Sonalee; Betts Marissa; Fahrbach Kyle; Chitnis Madhura; Polydefkis Michael;
展开▼
作者单位

Alnylam Pharmaceut Cambridge MA USA;

Alnylam Pharmaceut Cambridge MA USA;

Evidera Waltham MA USA;

Evidera Waltham MA USA;

Evidera Waltham MA USA;

Johns Hopkins Univ Dept Neurol Baltimore MD 21218 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Transthyretin amyloid polyneuropathy; indirect treatment comparison;

机译：Transthyretin淀粉样蛋白多变病;间接治疗比较;

相似文献

外文文献
中文文献
专利

1. Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy" [J] . Lin Hollis, Agarwal Sonalee, Betts Marissa, Expert opinion on pharmacotherapy . 2019,第7a12期

机译：回应编辑的信函“一个间接治疗比较Patisiran和Tafamidis治疗遗传性Transthyretin介导的淀粉样蛋白病变淀粉样蛋白病变的间接治疗比较”
2. Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy" [J] . Salvo E. M., Samjoo I. A., Tran D., Expert opinion on pharmacotherapy . 2019,第7a12期

机译：关于编辑的函件关于这篇文章：“Patisiran和Tafamidis对治疗遗传性Transthyretin介导的淀粉样蛋白阳性病的间接治疗比较伴有多变病变”
3. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy [J] . Planté-Bordeneuve, V.a, Lin, Expert opinion on pharmacotherapy . 2019,第1a6期

机译：Patisiran和Tafamidis治疗遗传性Transthyretin介导淀粉样淀粉样蛋白淀粉样蛋白淀粉样蛋白病变术的间接治疗比较
4. DEFINITION OF ORGAN INVOLVEMENT AND TREATMENT RESPONSE IN PRIMARY SYSTEMIC AMYLOIDOSIS (AL): A CONSENSUS OPINION FROM THE 10~(TM) INTERNATIONAL SYMPOSIUM ON AMYLOID AND AMYLOIDOSIS [C] . Morie A- Gertz, Ray Comenzo, Rodney H. Falk, International Symposium on Amyloidosis . 2005

机译：原发性全身淀粉样源病（AL）的器官参与和治疗反应的定义：10〜（TM）国际淀粉样蛋白和淀粉样症症的国际研讨会中的共识意见
5. Comparison of the Therapeutic Efficacy of Rheumatoid Arthritis Treatments [D] . Davis, Kacy. 2021

机译：类风湿性关节炎治疗治疗疗效的比较
6. A phase II open-label extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis [O] . Teresa Coelho, David Adams, Isabel Conceição, 2020

机译：II期开放式标签长期Patisiran治疗术遗传性Transthyretin介导（HATTR）淀粉样蛋白病的延长研究
7. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy [O] . Violaine Planté-Bordeneuve, Hollis Lin, Jared Gollob, 2018

机译：Patisiran和Tafamidis治疗遗传性Transthyretin介导的淀粉样蛋白淀粉样蛋白病变术的间接治疗比较

Response to the letter to the editor on 'an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy'

著录项

引文网络

相似文献

相关主题

期刊订阅